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ABSTRACT
Inverted papilloma (IP) is a locally destructive, benign neoplasm of the nose 
and paranasal sinuses with a high tendency for recurrence, a significant potential for 
malignancy, and an etiology that today is still uncertain. The expression of hormonal 
receptors in neoplastic tissues has been the focus of intensive research for its potential 
diagnostic, prognostic, and therapeutic significance. The aim of this study was to assess 
the potential estroprogestinic receptor expression in patients undergoing sinus surgery 
for IP. A retrospective study was carried out, on surgical specimens of 73 patients who 
underwent endoscopic sinus surgery for first manifestation of sinonasal IP (primitive 
IP group) and in 21 subjects who had developed a recurrence (relapsed IP group). The 
results of the immunohistochemical analysis of the first group showed the absence of 
receptor expression for PGR in all cases analyzed and the presence of a low positivity 
for ER in 11 cases (P > 0.082). Similarly, in the second group the results showed a low 
presence of ER receptors in 3 of the 21 cases (P > 0.068), while there was no evidence 
of PGR receptors in the examined samples. In addition, in 11 of the cases only 3 were 
considered positive (27.2%) showing a recurrence during follow-up (P > 0.068).
Our results suggest that the sinonasal IP is a benign tumor independent of estrogen 
and progesterone, and the receptors for these hormones are therefore unsuitable as 
predictors of relapse or possible prognostic indicators and therapeutic targets.
INTRODUCTION
The inverted papilloma (IP) of the nose and paranasal 
sinuses is a benign tumor that, today is the focus of research 
concerning the most recent acquisitions in terms of 
etiopathogenesis, pre- and post-operative clinical work-up, 
prognostic factors and different surgical strategies aimed at 
achieving a more radical exeresis and a lower relapse frequency.
There has been a growing number of interventions on 
the nasal side wall and a number of technological innovations 
over the last decade that, after due consideration, have led 
to targeted surgical approaches and less invasive demolition. 
On the etiological side, several studies have 
provided greater clarity on a topic still relegated to the 
probable association with the human papilloma virus 
(HPV), which has never been identified in cell cultures, 
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if not through molecular hybridization techniques, in 
which the HPV DNA was detected in 73% of the IPs [1], 
the RNA of HPV types 6 and 11 was found in 89% of 
sinonasal papillomas concomitant with similar forms in 
the genital tract [2], and DNA sequences HPV 6b and 11 
were isolated by Weber in 76% of cases [3]. 
On the other hand, especially in the last decade, there 
has been the identification in many cancers of the head-neck, 
renal, and breast district of receptors for sex hormones This 
is thanks to technological innovation in the biological field 
of a more sophisticated immunohistochemical methodology 
with greater sensitivity. This expression could therefore be 
the basis of a hormone-dependence, which could play a 
central role in prognosis and therapy [4–5]. On this basis, 
different pharmacological strategies are available to obtain 
volumetric tumour shrinkage and/or arrest of progression in 
various benign or malignant tumors including a reduction in 
time to progression and disease recurrence [6]. 
The aim of this study was to assess the potential 
estroprogestinic receptor expression in patients undergoing 
sinus surgery for IP, to identify new etiopathogenetic factors 
and/or co-factors useful for prognostic and therapeutic 
development.
RESULTS
At the histological examination, the IP showed 
an inverted pattern of growth with cords and nests of 
epithelium endophytically projecting into the underlying 
stroma (Figure 1). At higher magnification, the surface 
of the IP had from 5 to 30 layers of squamous, ciliated 
columnar, or intermediate epithelium with interspersed 
mucus-secreting cells. In all epithelial types, nuclei 
were generally small and uniform, with darkly staining 
chromatin and rare nucleoli. Mitoses were few and confined 
to the lower epithelial levels. Dilated ductal-like structures, 
lined by multiple layers of epithelium and terminating in 
smaller cellular nests, were usually observed. 
At the immunohistochemical examination, 
“primitive IP” showed negativity (score 0) for PGR 
expression in all cases (Figure 2) and low positivity 
(score 1) for ER in 11 cases (P > 0.082) (Figure 3). 
“Relapsed IP” showed low positivity (score 1) for ER 
receptors in 3 of the 21 cases (P > 0.068) (Figure 4), 
and negativity (score 0) for PGR expression in all cases 
(Figure 5). ER expression and sinonasal localization are 
summarized in Table 1. Moreover, cases of “primitive IP” 
with ER expression, 8 males (72.7%) vs 3 females (27.3%) 
(P < 0.044), showed a gender prevalence. In addition, 3 
cases (27.2%) with ER expression showed a recurrence 
during follow-up (P > 0.068). Overall, the number of cases 
positive for ER expression in the “primitive IP” group, and 
the number of cases with ER expression in the “relapsed 
IP” group did not represent a statistically significant 
sample compared with the negative cases. All cases of 
“primitive IP” and “relapsed IP” showed a mean labelling 
index (percentage of immunostained cells) for Ki67 of 
15% and no relationship between MIB-1 labelling index 
and estroprogestinic receptor expression was observed. 
DISCUSSION
The evaluation of expression and/or overexpression 
of hormone receptors in neoplastic tissues is now the 
fulcrum of many debates and scientific research. It seems 
clear that their expression implies and determines a variable 
degree of hormonal dependence. This principle has had 
a great impact in the treatment and prognosis of certain 
types of breast cancers. Anti-hormonal treatment with 
tamoxifen has provided encouraging results in controlling 
these tumors, also showing activity in preventing breast 
disease [7]. The presence of hormone receptors in other 
types of neoplasm has also been documented, although 
their clinical significance is not yet clear; and it has been 
documented that their expression in some cancer types 
does not necessarily predict the response to hormone 
therapy in prognostic and therapeutic approaches [8].
The expression of ER and PGR is also widely 
documented in the literature, even in normal and neoplastic 
tissues of the head and neck, but with contradictory results. 
Schuller et al., studied a series of 65 patients with different 
types of tumors in different locations of the head and neck; 
in this series most of the samples did not express receptors 
for ER and/or PGR. Only 2 out of 125 samples were 
considered significantly positive, the authors concluded 
that cancers of the head and neck should be considered 
hormone independent [9]. In another study Molteni 
et al. analyzed the expression of receptors in normal and 
neoplastic tissues in various sites of the head and neck. 
Classifying samples by anatomic origin have found 
significant levels of ER and PGR, particularly in normal 
parotid tissue and cancer, as well as in some normal and 
neoplastic mucosa of the floor of the mouth and nose [10].
The larynx has by far received the most attention 
regarding the study on sex hormone receptor expression. 
Ferguson et al. using immunohistochemical analysis 
in normal laryngeal tissues and laryngeal carcinomas, 
concluded that ER and PGR were both localized in the 
nucleus of cells and their expression was primarily in the 
vocal muscle in contrast to the rest of laryngeal epithelial 
tissue, and, in addition, no expression was found in squamous 
cell carcinomas of the larynx and hypopharynx [11]. 
Virolainen et al., documented the expression for ER and 
PGR in different head and neck cell lines in culture. They 
found significant levels of ER receptors in about 70% of 
laryngeal cells and in approximately 15% of cells derived 
from other head and neck locations. The distribution for 
PGR was more homogeneous, and they found that 80% of 
laryngeal cell lines and 55% of extralaryngeal cell lines were 
positive for receptors. On the basis of these results, they 
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Figure 3: A case of primitive IP with a low positivity for estrogen receptor (immunoperoxidase; 150×).
Figure 2: The epithelial cells of primitive IP were negative for progesterone receptor (immunoperoxidase; 100×).
Figure 1: IP characterized by an inverted pattern of growth with cords and nests of epithelium endophytically 
projecting into the underlying stroma (H&E; 100×).
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concluded that the hormone might be an additional treatment 
in the therapeutic protocol in selected cases of head and neck 
cancers [12].
Furthermore, Grenman et al. studied the in vitro 
effects of treatment with anti-tamoxifen in certain types 
of head and neck cancer, finding inhibition of growth 
in cell lines with significant ER and PGR expression, 
when these cells develop in the presence of tamoxifen 
citrate [7]. Based on these findings, a clinical trial by Urba 
et al. treated 12 patients with recurrent (on T) laryngeal 
squamous cell carcinomas with tamoxifen. The results of 
this trial, however, were discouraging, because the patients 
had no clinical response after treatment [13]. Another 
clinical trial was performed by Mattox et al. using the 
antiandrogen flutamide to treat 10 patients with laryngeal 
cancer and one patient with floor-of-the-mouth cancer 
with almost no results [14]. 
The characteristics of IP are now universally 
accepted: it is almost always unilateral, usually originates 
from the side wall of the nose, is more common in men 
than women (ratio of 4:l approximately), the highest 
incidence occurs in the sixth and seventh decades of life. 
Although IP is benign, it may be confused with a variety of 
other pathologies such as inflammatory polyps, respiratory 
epithelial adenomatoid hamartoma and low-grade 
adenocarcinomas [15–16]. The recognition of this entity 
is important as complete endoscopic excision is curative. 
The current limit of such an approach can be represented 
by a widespread involvement of a hyperpneumatization 
of frontal sinus, or lesions affecting the intracranial and 
infraorbital regions. In these circumstances, radical 
surgery can be better guaranteed by an external approach. 
These tumors also have a tendency to recur, are locally 
destructive and have significant association with 
squamous cell carcinoma (2% to 26% with an average of 
9.2%) [17]. The significantly higher incidence in males 
suggests possible sexual hormone dependence. Only two 
studies in 1994 and 1998 studied the expression of sex 
Figure 5: The epithelial cells of relapsed IP were negative for progesterone receptor (immunoperoxidase; 150×).
Figure 4: A case of relapsed IP with a low positivity for estrogen receptor (immunoperoxidase; 200×).
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hormones receptors on limited number of case histories 
are reported in the literature [18–19]. The analysis of 
these studies showed the absence of PGR-ER receptor 
expression or weakly positive for PR.  Even if IP is about 
four times more common in men than in women, we 
obtained a comparable number of samples from both sexes 
to eliminate the male bias in receptor expression. After 
making this initial selection, the tissue samples analyzed 
were randomly obtained. 
We found no PGR expression in the samples 
analyzed, except in 11 cases in the group with primary 
tumor and 3 cases in the group with relapsed tumor, 
which were weakly positive for ER (Table 1). These 
results obtained on a numerically significant sample 
and for the first time on a sample of patients with tumor 
recurrence, assign a role of an independent factor in the 
etiopathogenesis of sinonasal IP to the sex hormones 
examined. 
MATERIALS AND METHODS 
Study participants
In the period between 2006 and 2016, at the ENT 
Department of the University of Catania (Italy), in 
collaboration with the Section of Anatomic Pathology of 
the same University, a prospective study was carried out 
to identify the presence of receptors for estrogen (ER) and 
progesterone (PGR) in surgical specimens of 73 patients 
who had undergone sinus surgery for a first manifestation 
of sinonasal IP. In these patients, categorized as “primitive 
IP” group, for lesions limited to the middle meatus, anterior 
and/or posterior ethmoid sinuses and/or sphenoethmoidal 
recess, the endoscopic endonasal approach included an 
anterior and posterior ethmoidectomy, large middle meatal 
antrostomy, sphenoidotomy and partial and/or total middle 
turbinectomy. For lesions of the maxillary sinus, resection 
included, in addition to the previous surgical steps, also 
a medial maxillectomy with or without resection of the 
nasolacrimal duct. If the lesion involved the anterior and/
or inferior posterolateral wall of the maxillary sinus an 
intranasal resection of the Denker type with exposure of 
the piriform crest and subsequent drilling of the anterior 
wall of the sinus was carried out. Finally, the lesions that 
from the anterior ethmoid involved the ostium of the 
frontal sinus or the small lesions occupying the frontal 
sinus a frontal sinusotomy sec. Draf II or III was carried 
out. A medial maxillectomy using external approach was 
performed in only 5 cases (6.8%). In all the selected 
cases, the precise delimitation of resection margins, the 
application of a subperiosteal dissection and an en bloc 
and/or debulking removal, guaranteed the good outcome 
of the surgical radicality. 
The clinical and radiological follow-up was 
included in a range of 60–110 months, with prospective 
evaluation every two months during the first year and 
every four months thereafter. Of the 21 subjects who 
had developed a recurrence, categorized as “relapsed IP” 
group, the occurrence was within the first three years in 
29% (6 cases), between 3 and 5 years in 57% (12 cases) 
and between 5 and 10 years in 14% (3 cases). These 
subjects, therefore, underwent new revision surgery and 
new determination of receptor expression to estrogen and 
progesterone.
The patient population consisted of 41 (60.2%) 
men and 32 (39.8%) women with an average age of 58 
years (range 48–71 years) in the first group “primitive 
IP” and 13 (61.9%) men and 8 (38.1%) women with an 
average age of 65 years (range 53–78 years) in the second 
group “relapsed IP”. The demographic characteristics of 
both groups, as regards group division, gender, age and 
sinonasal localization are summarized in Tables 2, 3.
Statistical analysis was performed by using SPSS 
for WINDOWS (version 13.0; SPSS, Chicago, IL, USA). 
The results were analyzed using the non-parametric Mann-
Whitney test, which was used to assess the statistical 
significance and differences between categories. In all 
cases, P values of < 0.05 were considered statistically 
significant.
Anatomic pathology section
Four-mm serial sections from formalin-fixed, 
paraffin-embedded blocks of IP representative areas 
were cut for each case. Immunohistochemistry was then 
performed on the sections mounted on poly-L-lysine-
Table 1: Immunohistochemical analysis: number of cases/ER receptor expression
Localization primitive IP relapsed IP
Frontal sinus 10/1 2/0
Middle meatus 19/0 5/0
Maxillar sinus 16/6 6/2
Sphenoethmoidal recess 5/2 1/0
Anterior and/or posterior ethmoid 23/2 7/1
Total (%) (P value) 11 (15%) (0.082) 3 (27.2%) (0.068)
IP: Inverted Papilloma.
ER: Estrogen.
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coated glass slides. Deparaffinized and rehydrated 
sections were incubated for 30 min in 3% H2O2/methanol 
to quench endogenous peroxidase activity, and then rinsed 
for 20 min with phosphate-buffered saline (PBS) (Bio-
Optica M107, Milan, Italy). Non-specific protein binding 
was attenuated by incubation for 30 min with 5% horse 
serum in PBS. Sections were then placed in a microwave 
oven at 750 MHz for the revelation of antigenic sites. 
Specimens were incubated overnight with the estrogen 
receptor a antibody (monoclonal mouse, clone 1D5, at a 
dilution of 1:35, Dako Cytomation, Glostrup, Denmark), 
progesterone receptor antibody (polyclonal rabbit, at a 
dilution of 1:50, Dako Cytomation, Glostrup, Denmark) 
and MIB-1, a monoclonal antibody directed against 
the Ki-67 antigen (1:75, Dako Corporation, Glostrup, 
Denmark). The antibodies were applied directly to the 
section and the slides were incubated overnight (4°C) in 
a “humidified chamber”. The sections were washed three 
times with PBS at room temperature. Immune complexes 
were subsequently treated with the secondary biotinylated 
antibody and then detected by streptavidin peroxidase, 
both incubated for 30 min at room temperature (Vectastain 
ABC kit, Vector Laboratories, Burlingame, CA, USA). 
After rinsing with 3 changes of PBS, the immunoreactivity 
was visualized by development for 2 min with 0.1% 
3.3′-diaminobenzidine and 0.02% hydrogen peroxide 
(DAB substrate kit, Vector Laboratories Burlingame 
Calif., USA). Sections were counterstained with Mayer’s 
hamatoxylin, mounted with permanent mounting medium 
and examined by light microscopy.
A semi-quantitative assessment of estrogen and 
progesterone receptor expression was performed assigning 
cases to one of the three following categories: (a) score 0, 
when the stained cells were from 0 to < 5% of the total; (b) 
score 1, when the stained cells were from > 5 to < 50% of 
the total cell population; (c) score 2, when the stained cells 
were > 50%. Positive controls consisted of tissue specimen 
sections of human breast tissue. A negative control 
was performed in all cases by substituting the primary 
antibody with normal mouse serum. Negative controls in 
all instances resulted in a negative immunoreactivity for 
estrogen and progesterone receptors. Only nuclear staining 
of epithelial cells was evaluated.
MIB-1 labeling index was evaluated in the highest 
immunoreactivity fields. It was expressed as a percentage 
and was determined by dividing the number of positive 
staining nuclei by 1000 tumor cells.
CONCLUSIONS
Our results suggest that sinonasal IP is a benign 
tumor independent of estrogen and progesterone, and the 
receptors for these hormones are therefore unsuitable as 
predictors of relapse or possible prognostic indicators and 
therapeutic targets.
Table 2: Demographic characteristics
Groups primitive IP - n (%) relapsed IP – n (%)
Men 41 (56.1%) 13 (61.9%)
Woman 32 (43.9%) 8 (38.1)
Age 59 (range 48–71) 65 (range 53–78)
Symptomatology Unilateral nasal obstruction (95%) 
Serous and/or blood-serous rhinorrhea (53%)
Headache (27%)
Epistaxis (5%)
Facial pain (5%)
IP: Inverted Papilloma.
Table 3: Sinonasal localization
Localization primitive IP relapsed IP
Frontal sinus 10 (13.7%) 2 (9.6%)
Middle meatus 19 (26%) 5 (23.8%)
Maxillar sinus 16 (22%) 6 (28.5%)
Sphenoethmoidal recess 5 (6.8%) 1 (4.8%)
Anterior and/or posterior ethmoid 23 (31.5%) 7 (33.3%)
Total 73 21
IP: Inverted Papilloma.
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